On November 13, Callodine filed paperwork with the SEC revealing they bought 765,275 shares of FCPT. That’s a pretty hefty stake-$18.67 million, to be exact. It’s their first time holding FCPT in their quarterly report, which feels like a secret handshake with a company that’s been quietly doing its thing. I wonder if they’re betting on a comeback or just hedging their bets with a predictable cash flow.
The filing of November 12th reveals not merely a financial transaction, but a strategic declaration. With the acquisition of these additional shares, Triata now holds 2 million ACMR shares valued at $78.39 million – a position constituting 9.15% of their 13F portfolio, and securing its place as their fourth most significant alliance. This consolidation occurs amidst a broader portfolio worth $856.81 million, where ACM Research now stands alongside internet darlings such as PDD and VNET in what might be considered a most unconventional marriage of interests.
The details are as crisp as a fresh apple: according to a filing with the Securities and Exchange Commission (SEC), this entire exit happened during the third quarter. The transaction value? A neat $12.18 million, calculated from average prices that could rival the complexity of a Rubik’s Cube.
Sourcerock, in a move that screams “I’ve seen the future and it’s a spreadsheet,” added 1.18 million shares of CRC, bringing their total stake to 3.18 million. Now, their position is worth $169.14 million. Because if you’re going to lose money, you might as well do it in bulk.
The dividend hunter, armed with nothing but a calculator and a tenuous grasp of beta, finds themselves ensnared in a paradox: IGIB sprawls like a bureaucratic archive, its 2,987 holdings a testament to the illusion of control, while VCIT, with its 343 bonds, whispers promises of clarity and marginally higher yield. Yet both are bound by the same invisible chains-interest rates, credit spreads, the spectral hand of market anxiety.
The fund’s XPeng stake, once a proud 8% of its assets under management, now rests at zero. A hollow victory, perhaps, for a market where numbers outlive sentiment. The fund’s top holdings now read like a ledger of lesser gods: AEG, SATS, VCSH-each a name etched in the cold script of spreadsheets.
In this age of fleeting digital whims and ephemeral trends, two Vanguard offerings stand as steadfast companions for the long journey: the Vanguard S&P 500 Growth ETF (VOOG 0.73%) and the Vanguard Information Technology ETF (VGT 0.82%). With a thousand dollars and a heart attuned to the slow unfolding of value, one might plant these seeds in the fertile soil of compounding time.
While the S&P 500 ETFs are the celebrities of the market, the Mid-Cap ETF is the quiet friend who always brings a thoughtful gift. Its portfolio, a mosaic of companies valued between $2 billion and $10 billion, occupies a curious liminal space-neither the fledgling chaos of startups nor the bureaucratic inertia of giants. (Imagine a teacup that’s neither hot nor cold, but somehow always just right.)
If you wander into the marketplace of metrics, you will find one called the Shiller P/E-crafted by a chap with a Nobel prize and probably far too much free time-used to smooth out the cyclic chaos of corporate earnings, much like a philosopher smoothing his philosopher’s beard after a long day pondering the nature of business cycles. It divides the current value of the S&P 500 (^GSPC 0.03%) by the inflation-adjusted earnings over the last decade-a period which, if recorded as a novel, would be titled “The Long, Long Tale of Excess and Hangovers.” The long-term average hovers around 17, but currently, the ratio is straining at roughly 40-like a over-fed bat trying to squeeze through a tiny hole. Historically, whenever this ratio has lingered above 30 for extended periods, the market has experienced a downturn of at least 20%. The only time it reached beyond 40 was during the dot-com bubble-a period where everyone thought the internet was an infinite jug of moonshine that would keep fueling the party forever.
Things That Make Me Nervous (But Probably Shouldn’t):